Oxford Therapeutics Limited

Oxford Therapeutics Limited is focused on the development and distribution of behaviour-change therapies in the weight-loss arena. Our comprehensive, fully downloadable programme is uniquely designed, drawing from over 15,000 hours of 1:1 clinical treatment time. Our commitment to integrating extensive insights, gained from the treatment of more than a thousand patients, ensures that our therapies are effective and grounded in solid, real-person trials.

Award-Winning Programme

The Oxford Therapeutics weight-loss programme has the potential to become the preferred choice for doctors seeking a proven behaviour change, diet/exercise programme for their patients, to partner with their prescribing of GLP-1 receptor agonists. The programme introduces weight-loss patients to a holistic approach, addressing both psychological and behavioural aspects. We agree with others that the introduction of a behaviour change, diet/exercise programme is a vital component in the weight loss journey of patients.

Food and Drug Administration

In the United States, the Food and Drug Administration (FDA) has mandated that GLP-1 receptor agonists weight-loss medications be prescribed in conjunction with a behavioural change programme. The FDA’s approach aims to ensure that patients not only lose weight but also adopt healthier lifestyle habits, which is crucial for maintaining their weight loss in the long term. This regulatory stance underscores the necessity of a comprehensive treatment plan, as detailed on the pages of this website.

NICE

Similarly, the National Institute for Health and Care Excellence (NICE) in the United Kingdom advocates a multifaceted approach to weight management. NICE recommends that weight-loss medications be integrated into a comprehensive weight management programme. The guidance from NICE emphasises the importance of addressing obesity through a holistic and sustainable approach, aiming to deliver long-term health benefits and improved quality of life for patients. Marion Shirran, the co-founder of Oxford Therapeutics Ltd, is a NICE stakeholder and a member of the All-Party Parliamentary Group on Obesity.

A Seamless Solution

The innovative weight-loss programme stands out as a potential solution in weight management, combining clinical expertise with comprehensive behavioural change interventions incorporating diet and exercise recommendations. Consequently, it is well-positioned to seamlessly assist doctors in their endeavours to help patients achieve and maintain realistic weight-loss goals while promoting a healthier and more sustainable lifestyle. On the following pages, we provide details of the extensive, downloadable programme, and the partnership options available to Healthcare Professionals.

Oxford Therapeutics

Martin and Marion Shirran, the founders of Oxford Therapeutics were responsible for developing the unique upgrade to the traditional Cognitive Behaviour Therapy (CBT) approaches and techniques. It’s known as Tactile Cognitive Behaviour Therapy, or TCBT. “In a single moment, you have elevated CBT from being a completely passive therapy into a useful tactile alternative!” (Dr Theano Kalavana). Academics, including Professor Windy Dryden, of Goldsmiths University London, and Professor Philip Zimbardo, of Stanford University, in San Francisco, have endorsed the therapy. Professor Zimbardo wrote the foreword to our book about TCBT, published by Hay House.

Following the growing use of the programme by orthopaedic surgeons, seeking reliable, pre-surgery, weight-loss interventions for their hip and knee replacement patients, doctors are now considering it as a potential component/partner, when prescribing GLP-1 receptor agonists.

---

Stakeholder in NICE – National Institute for Health and Care Excellence

Marion Shirran, as a director of Oxford Therapeutics Limited, is a registered Stakeholder in NICE – National Institute for Health and Care Excellence.

---

All-Party Parliamentary Group on Obesity

Marion is proud to be a member of the All-Party Parliamentary Group on Obesity.

---

Please visit the contact page for email or telephone details.